Tempus AI Nears Profitability as Operating Leverage Emerges

Tempus AI’s Q4 2025 gross profit jumped 94.7% year over year, with adjusted EBITDA of $12.9 million and 2026 guidance of about $65 million, signaling improving operating leverage. The offset is continued GAAP net losses of $54.2 million, driven by stock-based compensation and acquisition-related non-cash costs, so the path to GAAP profitability remains unclear. The article is constructive on fundamentals and guidance, but still highlights elevated loss visibility and valuation dependence on future scale.

Analysis

TEM is transitioning from a “story stock” to a “scale compounding” name, but the market is still likely underestimating how much of the 2026 EBITDA bridge depends on mix, not just volume. The key second-order effect is that diagnostics growth and data monetization reinforce each other: as the installed base of clinical activity deepens, the company can sell more high-margin data products without equivalent SG&A growth, which should make incremental margins look much better than headline revenue growth implies.

That said, the biggest overhang is not operating performance but quality of earnings. If stock-based comp remains structurally high, GAAP losses can persist even while adjusted metrics improve, which keeps the stock anchored to confidence rather than fundamentals. In that setup, any disappointment in reimbursement timing or data contract conversion matters disproportionately because the valuation already prices a durable operating-leverage narrative at roughly in-line sales multiples.

Relative to HIMS and GDRX, TEM is the cleaner AI-enabled healthcare operating leverage play, but also the one with the most fragile path to GAAP credibility. HIMS has a more visible consumer monetization engine and near-term profitability support, while GDRX is more of a margin-defense and mix-shift story; TEM sits in between, with higher upside if data monetization scales but a larger downside gap if the market stops rewarding adjusted EBITDA and starts discounting dilution. The consensus seems to be treating 2026 EBITDA as validation, when the real inflection is whether the business can convert growth into durable free cash flow before compensation expense overwhelms the optics.

The contrarian read is that the current multiple is not obviously cheap if the company remains GAAP-loss heavy; the market may be paying for a future state that is still 12-24 months away. The better trade is to own TEM only if you believe the next two quarters will show improving dollar retention and operating discipline, otherwise the risk/reward favors owning the more self-funded peers and waiting for a pullback in TEM on any evidence that EBITDA is scaling faster than dilution is controlled.

Key Decisions for Investors

• Long TEM on a 3-6 month horizon only on pullbacks; target a rerating if 2026 EBITDA guidance proves conservative, but cut if SBC remains elevated and the market shifts focus from adjusted EBITDA to GAAP losses.
• Pair trade: long HIMS / short TEM for the next 1-2 quarters if you want healthcare growth exposure with cleaner near-term earnings visibility; HIMS has the better catalyst path to positive EPS, TEM has higher execution and accounting-risk drag.
• Small long GDRX vs short TEM basket if you expect the market to reward disciplined margin expansion over AI/data hype; GDRX’s lower-growth but more controllable earnings profile should hold up better in a risk-off tape.
• Use call spreads rather than outright longs in TEM into the next earnings window to capture a positive surprise while limiting downside from any setback in reimbursement, data conversion, or SBC optics.
• If TEM sells off on any guidance miss but gross profit still accelerates, add on weakness only if the forward revenue-to-adjusted EBITDA conversion remains intact; otherwise treat it as a valuation reset, not a dip-buy.